<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515305</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-15-003</org_study_id>
    <nct_id>NCT02515305</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of Perrigo's product to an
      FDA approved product for the treatment acne vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from Baseline in inflammatory (papules and pustules) lesions</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change from Baseline in non-inflammatory (open and closed comedones) lesions</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">890</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin and Benzoyl Peroxide Gel (combination)</intervention_name>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel (combination)</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent/assent

          2. Healthy male or non-pregnant females, 12 to 40 years of age, inclusive

          3. Definite clinical diagnosis of acne vulgaris with an inflammatory lesion (papules and
             pustules) count between 20 and 50 and a non-inflammatory (open and closed comedones)
             lesion count between 25 and 100 and no more than 2 nodulocystic lesions (i.e., nodules
             and cysts) including those present on the nose.

          4. Baseline IGA score of 3 or 4 on a scale of 0 to 4.

          5. Willing and able to understand and comply with the requirements of the study, apply
             the medication as instructed, refrain from use of all other topical acne medication or
             topical antibiotics during the 12-week treatment period, return for the required
             treatment period visits, comply with therapy prohibitions, and are able to complete
             the study.

          6. Be in general good health and free from any clinically significant disease, other than
             acne vulgaris, that might interfere with the study evaluations.

          7. Females of childbearing potential willing to use an acceptable form of birth control

        Exclusion Criteria:

          1. Females who are pregnant, nursing, or planning a pregnancy within the study
             participation period

          2. More than 2 facial nodulocystic lesions (i.e. nodules and cysts).

          3. Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne,
             etc.).

          4. Active cystic acne or Polycystic Ovarian Syndrome.

          5. History or presence of Crohn's disease, ulcerative colitis, regional enteritis,
             inflammatory bowel disease, pseudomembranous colitis, chronic or recurrent diarrhea or
             antibiotic-associated colitis.

          6. Use of neuromuscular blocking agents (nondepolarizing agents and depolarizing agents)
             Subjects who have had general anesthesia for any reason and subjects who have received
             neuromuscular blocking agents within 14 days prior to study entry will be excluded
             from study participation.

          7. Presence of any other facial skin condition that might interfere with acne vulgaris
             diagnosis and/or assessment (e.g., on the face: rosacea, dermatitis, psoriasis,
             squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid
             acne, steroid folliculitis, sunburn or bacterial folliculitis).

          8. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere
             with diagnosis or assessment of acne vulgaris.

          9. History of unresponsiveness to topical Clindamycin Phosphate and/or benzoyl peroxide
             therapy.

         10. Use of systemic Clindamycin products 4 weeks (30 days) prior to baseline or throughout
             the study.

         11. History of hypersensitivity or allergy to Clindamycin Phosphate, benzoyl peroxide
             and/or any ingredient in the study medication.

         12. Use within 6 months (180 days) prior to baseline or during the study of oral retinoids
             (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day
             (multivitamins are allowed).

         13. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit
             1/Day 1 (Baseline).

         14. Use within 30 days (1 month) prior to baseline or during the study of therapeutic
             vitamin D supplement (daily multivitamins with total 800IU Vitamin D are allowed).

         15. Use of medications known to exacerbate acne (Vitamin B12, lithium, corticosteroids;
             Vitamin B12, etc. as part of a multivitamin regimen is allowed).

         16. Start or change of dose of hormonal treatment (oral, implanted, topical contraceptives
             and androgens) 3 months (90 days) prior to baseline or throughout the study. Use of
             such therapy must remain constant during the study.

         17. Use of medicated make-up throughout the study and significant change in the use of
             consumer products within 30 days (1 month) of study entry and throughout the study
             (other than study supplied cleanser and lotion).

         18. Use within 30 days (1 month) prior to baseline or during the study of 1)
             spironolactone, 2) systemic steroids*, 3) systemic (e.g., oral or injectable)
             antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids which
             require a 6-month washout), or 5) immunosuppressive agents**. (*Intranasal and inhaled
             corticosteroids do not require a washout and may be used throughout the study if at a
             stable and standard dose.)** Subjects may use systemic anti-inflammatory agents (i.e.,
             NSAIDs (Ibuprofen or Aspirin) for pain relief) as needed (with no more than 7 days of
             consecutive use) throughout the study. Prophylactic use of low dose Aspirin 81 mg is
             allowed. *** Subjects may use Acetaminophen for pain relief, as needed throughout the
             study

         19. Use within 14 days (2 weeks) prior to baseline or during the study of 1) topical
             steroids, 2) topical retinoids, 3) topical anti-acne medications (e.g. Benzoyl
             peroxide, retinoids, azelaic acid, α-hydroxy/glycolic acid, Clindamycin, etc.)
             including OTC preparations 4) topical anti-inflammatory agents, or 5) topical
             antibiotics.

         20. Use on the face within 1 month (30 days) prior to baseline or during the study of 1)
             cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne
             surgery, 5) intralesional steroids, or 6) x-ray therapy.

         21. Use of medicated cleansers (e.g. benzoyl peroxide, salicylic acid, sulfur or
             triclosan) within 2 weeks (14 days) of study start and throughout the study.

         22. Subject consumes excessive alcohol, abuses drugs, or has a condition that could
             compromise the subject's ability to comply with study requirements.

         23. Use of Antipruritics, including antihistamines within 24 hours (1day) of all study
             visits (Visit 1 through Visit 4).

         24. Participation in any clinical study involving an investigational product, agent or
             device ( that might influence the intended effects or mask the side effects of study
             medication ) in the 4 weeks (30 days) prior Visit 1/Day 1 (Baseline) or throughout the
             study.

         25. Previous enrollment in this study or current enrollment in this study at another
             participating site.

         26. Employee (or employee's family member) of the research center or private practice, or
             subjects who have a conflict of interest.

         27. Use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun 1 week
             (7 days) prior to enrollment and throughout the study.

         28. Subjects who in the opinion of the investigator, are unlikely to be able to follow the
             restrictions of the protocol and complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <disposition_first_submitted>June 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2016</disposition_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

